Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the ability of a protected agent to prevent the pigmentation under visible light exposures (VL) using two different simulators in healthy volunteers
The sunscreens usually used as photoprotectors are known to protect in the UV domain (UVB and UVA). However, until recently visible light (400-700 nm) was considered as devoid of any photobiological effects on cutaneous tissue. Over the last two decades, with the development of photodynamic therapies and various dermatological treatments using visible laser light, several studies have reconsidered the cutaneous effect of visible light on the skin, in particular the induction of pigmentation.
This study intends to validate two simulators on visible light exposures with a referent solar formula on visible light protection.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Product 1 | The tested product 1 was applied on 2 zones (one zone on each hemi-back), by gentle massage, according to the randomization list, 15 to 30-minutes before the Visible Light exposure. The application was done during 4 consecutive days (From Day 1 to Day 4). |
| |
| Untreated zone | 2 non-treated control zones (one zone on each hemi-back) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Visible Light Exposure - Treated zone - Left hemi-back | Other | The treated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application. |
| Measure | Description | Time Frame |
|---|---|---|
| Biophysical non-invasive assessment of skin color by using Chromameter® between the exposed zone (ZE) and non-exposed zone (ZNE) | Pigmentation (Delta E - calculated values) | At Day 1 before treatment (baseline), then Day 2, Day 3, Day 4, Day 5 (24 hours after each Visible Light exposure) and at Day 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Biophysical non-invasive assessment of skin color by using Chromameter® between the exposed zone (ZE) and non-exposed zone (ZNE) | Pigmentation : Individual Typologic Angle (ITA° - calculated value) based on Delta L* and Delta b* - calculated values) | At Day 1 before treatment (baseline), then Day 2, Day 3, Day 4, Day 5 (24 hours after each Visible Light exposure) and at Day 12. |
Not provided
Inclusion Criteria:
Healthy female or male volunteer from 18 to 50 years old
Skin type III-IV according to the Fitzpatrick classification
Average ITA° (Individual Typologic Angle calculated value) on the back between 18° and 32° at screening and inclusion visits with an allowed difference of ± 2° between screening and inclusion visits
Uniform skin color over the four zones (difference in ITA° between each zone should not be more than 4°)
Absence of freckles, naevi, hypo or hyper pigmented regions, hairs and marks of bronzing on the investigational area on the back
Female subject of childbearing potential, who is not sexually active, or using an effective contraceptive method* for at least one month before the beginning of the study, and throughout the study or menopausal female (with absence of menstruations for less than one year) or post-menopausal female (with absence of menstruations for more than one year)
*Effective contraceptive methods: sexually active female of childbearing potential should either be surgically sterile (oophorectomy, hysterectomy or tubal ligation), or should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm or cervical cap with intravaginal spermicide, intravaginal device, intrauterine device (IUD), condom with spermicide
Female of childbearing potential or menopausal female (with absence of menstruations for less than one year) willing to undergo urine pregnancy test
Subject willing and able to fulfil the study requirements and schedule
Subject informed about the study objectives and procedures, and able to understand them
Subject who has given written informed consent
Exclusion Criteria:
Not provided
Not provided
Healthy male and female volunteers from 18 to 50 years old with phototype III to IV according to the Fitzpatrick scale and with an ITA° between 18° to 32° at Screening
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CIDP Biotechnology S.R.L | Bucharest | 011607 | Romania |
Not provided
Not provided
Not provided
Not provided
| Visible Light Exposure - Treated zone - Right hemi-back | Other | The treated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), 15 to 30 minutes after application. |
|
| Visible Light Exposure - Untreated zone - Left hemi-back | Other | The untreated zone located on the left side of the hemi-back was exposed to Visible Light with the simulator 1 to induce skin pigmentation (144J/cm2), as the same time as the treated zone. |
|
| Visible Light Exposure - Untreated zone - Right hemi-back | Other | The untreated zone located on the right side of the hemi-back was exposed to Visible Light with the simulator 2 to induce skin pigmentation (144J/cm2), as the same time as the treated zone. |
|
| Clinical investigator's assessment by using clinical scale | Visual scoring of pigmentation, using a pigmentation 14-point scale with 0 (Absence), 1 (Barely visible), 2 (Very pale brown -), 3 (Very pale brown), 4 (Very pale brown +), 5 (Pale brown -), 6 (Pale brown), 7 (Pale brown +), 8 (Brown -), 9 (Brown), 10 (Brown +), 11 (Pronouced brown -), 12 (Pronouced brown), 13 (Pronouced brown +) Visual scoring of erythema, using an erythema 14-point scale with 0 ((Absence), 1 (Barely visible), 2 (Very pale pink -), 3 (Very pale pink), 4 (Very pale pink +), 5 (Pale pink -), 6 (Pale pink), 7 (Pale pink +), 8 (Pink -), 9 (Pink), 10 (Pink +), 11 (Pronouced pink -), 12 (Pronouced pink), 13 (Pronouced pink +) | At Day 1 before treatment (baseline), then Day 2, Day 3, Day 4, Day 5 (24 hours after each Visible Light exposure) and at Day 12. |
| Safety and Local Tolerance | Safety was assessed by recording Adverse Events, including cutaneous reactions related to Visible Light exposures or Investigational Product (local intolerance). | From the informed consent signature date until the end of the study Day 12 |
| Biophysical non-invasive assessment of skin color by using Chromameter® between the exposed zone (ZE) and non-exposed zone (ZNE) | Erythema (Delta a* - calculated value) | At Day 1 before treatment (baseline), then Day 2, Day 3, Day 4, Day 5 (24 hours after each Visible Light exposure) and Day 12. |